Evidence map›Paper›PMID 26517194›Full record

ArticleCell cycle (Georgetown, Tex.)2015

ATM serine-1981 phosphorylation is a plausible biomarker.

Christopher J Bakkenist, Jan H Beumer, John C Schmitz

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Phase I study of veliparib in combination with gemcitabine.Cancer chemotherapy and pharmacology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christopher J Bakkenista Departments of Radiation Oncology and Pharmacology and Chemical Biology ; University of Pittsburgh School of Medicine, Hillman Cancer Center ; Pittsburgh , PA USA.
Jan H Beumerb Department of Pharmaceutical Sciences ; University of Pittsburgh School of Pharmacy, University of Pittsburgh School of Medicine, Hillman Cancer Center ; Pittsburgh , PA USA.
John C Schmitzc Department of Medicine ; University of Pittsburgh School of Medicine, Hillman Cancer Center ; Pittsburgh , PA USA.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
NCI ET-CTN with Phase i Emphasis at UPCIUM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani · 2014 to 2026
$9.1M
Regulation of DNA replication fork progression by ATM kinase activityR01CA148644 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAKKENIST, CHRISTOPHER J. · 2011 to 2015
$1.3M
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA148644NCI NIH HHS UM1 CA186690
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAtaxia Telangiectasia Mutated ProteinsBiomarkersBiomarkers, TumorDNA DamageHumansNeoplasmsPhosphorylationSerineAtaxia Telangiectasia Mutated ProteinsATM protein, humanBiomarkersBiomarkers, TumorSerine

Identifiers

PMID26517194
PMCPMC4825586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.